MARKET

PRTK

PRTK

Paratek Pharmace
NASDAQ
2.260
0.000
0.00%
After Hours: 2.260 0 0.00% 16:01 11/28 EST
OPEN
2.260
PREV CLOSE
2.260
HIGH
2.320
LOW
2.220
VOLUME
340.62K
TURNOVER
0
52 WEEK HIGH
4.950
52 WEEK LOW
1.600
MARKET CAP
125.54M
P/E (TTM)
-1.3363
1D
5D
1M
3M
1Y
5Y
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Benzinga · 11/04 16:54
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 21:45
Paratek Pharmaceuticals Q3 EPS $(0.38) Misses $(0.29) Estimate, Sales $30.21M Miss $34.19M Estimate
Benzinga · 11/03 20:43
Paratek Pharmaceuticals GAAP EPS of -$0.38, revenue of $30.2M
Seekingalpha · 11/03 20:26
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study for the Treatment of Pulmonary Anthrax -- Announced Comm...
GlobeNewswire · 11/03 20:05
-- Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Reports Q3 Revenue $30.2M
-- Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Reports Q3 Revenue $30.2M
MT Newswires · 11/03 16:34
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other pub...
GlobeNewswire · 11/01 20:05
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other pub...
GlobeNewswire · 11/01 12:00
More
About PRTK
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The Company's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.

Webull offers kinds of Paratek Pharmaceuticals Inc stock information, including NASDAQ:PRTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTK stock methods without spending real money on the virtual paper trading platform.